Bristol-Myers Squibb: all 2,184 studies

Page 12 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy ParticipantsCompletedNCT04882150Phase 1
• A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT04860466Phase 1
• Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedNCT04855136Phase 1
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult ParticipantsCompletedNCT04839809Phase 1
• A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in JapanCompletedNCT04828772
• A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in JapanCompletedNCT04826536
• A Study to Assess Safety of Nivolumab in Routine Oncology Practice in ChinaCompletedNCT04825873
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
• A Study to Explore the Effect of Food Before a Single Dose of SitravatinibCompletedNCT04800614Phase 1
• A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04794010
• Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active, not recruitingNCT04793958Phase 3
• Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04789655Phase 1
• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of SitravatinibCompletedNCT04772612Phase 1
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseTerminatedNCT04766476Phase 1
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy ParticipantsCompletedNCT04763226Phase 1
• A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyTerminatedNCT04748848Phase 1
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy ParticipantsCompletedNCT04736134Phase 1
• A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MMTerminatedNCT04730505Phase 1
• A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female ParticipantsCompletedNCT04718636Phase 1
• A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT04702464Phase 1
• BMS-986325 in Healthy Participants and Participants With Primary Sjögren's SyndromeTerminatedNCT04684654Phase 1
• A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04674813Phase 1
• Effect of BMS-986165 on the Blood Levels of MetforminCompletedNCT04671953Phase 1
• Metabolism and Excretion of [14C]CC-90001 in Healthy Male SubjectsCompletedNCT04655898Phase 1
• A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean ParticipantsWithdrawnNCT04649710Phase 1
• Expanded Access for MarizomibNo longer availableNCT04644107
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of OzanimodCompletedNCT04639115Phase 1
• A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentCompletedNCT04634149Phase 1
• A Study of CC-90011 and Comparators in Participants With Prostate CancerCompletedNCT04628988Phase 1
• Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)CompletedNCT04618081
• Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic ImpairmentCompletedNCT04573582Phase 1
• Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male ParticipantsCompletedNCT04567667Phase 1
• A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male ParticipantsCompletedNCT04560738Phase 1
• A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in FranceActive, not recruitingNCT04550247
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy ParticipantsCompletedNCT04550195Phase 1
• A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedNCT04540705Phase 1
• A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04536961Phase 1
• A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult SubjectsCompletedNCT04528290Phase 1
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy ParticipantsCompletedNCT04515628Phase 1
• A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyCompletedNCT04500535
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2
• Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled SyringeCompletedNCT04493567Phase 1
• A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusCompletedNCT04493541Phase 1
• A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell TransfusionsCompletedNCT04477850Phase 2
• Participant Reported Outcomes and Treatment Experiences in Kidney CancerCompletedNCT04472663
• Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCompletedNCT04470778Phase 1
• A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)CompletedNCT04468815Phase 1
• A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory LymphomasTerminatedNCT04464798Phase 1
• A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235WithdrawnNCT04464577Phase 1
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
• Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy ParticipantsCompletedNCT04444050Phase 1
• A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
• Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT04428788Phase 1
• A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04394650Phase 1
• Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult SubjectsCompletedNCT04373187Phase 1
• A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaTerminatedNCT04336982Phase 1
• Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedNCT04330664Phase 1
• A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed GlioblastomaTerminatedNCT04324840Phase 1
• A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTerminatedNCT04311710Phase 1
• Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy AdultsCompletedNCT04310527Phase 1
• A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult ParticipantsCompletedNCT04305899Phase 1
• Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy ParticipantsWithdrawnNCT04301310Phase 1
• A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male SubjectsCompletedNCT04297124Phase 1
• Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male ParticipantsCompletedNCT04269356Phase 1
• A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677CompletedNCT04268394Phase 1
• A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same TimeCompletedNCT04263350Phase 1
• Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04249284Phase 1
• A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2
• A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney FunctionCompletedNCT04237831Phase 1
• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1
• Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminCompletedNCT04231435Phase 1
• A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver ImpairmentCompletedNCT04225936Phase 1
• A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese SubjectsCompletedNCT04211558Phase 1
• Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy SubjectsCompletedNCT04211545Phase 1
• A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy VolunteersCompletedNCT04209699Phase 1
• A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT04196491Phase 1
• A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)Active, not recruitingNCT04196452
• A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy ParticipantsCompletedNCT04175925Phase 1
• A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab TherapyCompletedNCT04161911
• A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy ParticipantsCompletedNCT04154800Phase 1
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2
• Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active MetabolitesCompletedNCT04149678Phase 1
• An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in AustraliaCompletedNCT04146324
• A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the USCompletedNCT04141228
• Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)TerminatedNCT04140305Phase 3
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1
• A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of StrokeCompletedNCT04126486Phase 4
• A Study to Assess the Drug-drug Interaction of BMS-963272 and RosuvastatinCompletedNCT04124003Phase 1
• A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy AdultsCompletedNCT04116632Phase 1
• The Effects Diflunisal on the Levels of BMS-986165 in Healthy ParticipantsCompletedNCT04113668Phase 1
• A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedNCT04112498Phase 1
• Pharmacogenetics Sampling of the CC-90007-CP-003 Study CohortCompletedNCT04097704
• Japanese Pharmacokinetic Bridging Study for CC-93538CompletedNCT04096105Phase 1
• A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life SettingCompletedNCT04089839
• Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT04089527Phase 1
• An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.CompletedNCT04086719Phase 1
• A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy ParticipantsWithdrawnNCT04082741Phase 1
• A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327CompletedNCT04069143Phase 1

← Bristol-Myers Squibb overview and focus areas